Study Details
A phase 1 study to investigate the mechanism of action of Ipragliflozin
This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).
Clinicaltrials.gov ID
The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
Astellas Study ID
The unique identification code given by the study sponsor.
1941-CL-0050
EudraCT ID
The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).
2010-024070-19
Condition
Adult Onset Diabetes
Phase
These clinical trials are usually the first time an experimental treatment is studied in a small group of people.
Phase 1
Age
35 years - 65 years
Sex
Female & Male
Product
N/A
Type
A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
Interventional
Trial Dates
Oct 2011 - Feb 2012
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment number
44
An exploratory study to investigate the effects of ipragliflozin (ASP1941) on glucose homeostasis and urinary glucose excretion in healthy subjects and subjects with type 2 diabetes mellitus (T2DM)
Study summary
Study documents
Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A phase 1 study to investigate the mechanism of action of Ipragliflozin? Contact us by filling our your information to the right and we’ll respond to you.